Biohaven (NYSE:BHVN) Sees Strong Trading Volume – Here’s What Happened

Posted by Francis Steltz on Aug 26th, 2026

Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 1,719,094 shares were traded during trading, a decline of 33% from the previous session’s volume of 2,547,931 shares.The stock last traded at $14.4680 and had previously closed at $14.38.

Analyst Ratings Changes

A number of brokerages have commented on BHVN. Royal Bank Of Canada raised their price target on shares of Biohaven from $22.00 to $23.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 11th. Morgan Stanley upped their price target on Biohaven from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. HC Wainwright reiterated a “neutral” rating and set a $10.00 price objective on shares of Biohaven in a research note on Tuesday, May 26th. Bank of America reissued an “underperform” rating and set a $11.00 price target (down from $12.00) on shares of Biohaven in a report on Monday, June 29th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Biohaven in a report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Biohaven presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.75.

View Our Latest Stock Analysis on Biohaven

Biohaven Trading Up 6.0%

The stock has a market cap of $2.30 billion, a P/E ratio of -3.28 and a beta of 1.26. The company has a current ratio of 4.73, a quick ratio of 4.73 and a debt-to-equity ratio of 21.23. The business’s fifty day simple moving average is $14.67 and its 200 day simple moving average is $11.78.

Biohaven (NYSE:BHVN – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). As a group, analysts expect that Biohaven Ltd. will post -3.29 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC raised its position in shares of Biohaven by 1,145.9% during the first quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock worth $148,214,000 after acquiring an additional 16,127,247 shares during the last quarter. BlackRock Inc. acquired a new stake in Biohaven in the second quarter worth about $196,574,000. Suvretta Capital Management LLC raised its holdings in Biohaven by 83.0% during the 4th quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock worth $116,140,000 after purchasing an additional 4,666,666 shares during the last quarter. Stifel Financial Corp raised its holdings in Biohaven by 50.3% during the 4th quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock worth $112,221,000 after purchasing an additional 3,328,506 shares during the last quarter. Finally, Jupiter Topco LLC acquired a new position in Biohaven during the 2nd quarter valued at about $127,852,000. 88.78% of the stock is currently owned by institutional investors.

About Biohaven

(Get Free Report)

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.